Epizyme reported $22.36M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Abbott ABT:US $ 6324M 584M
Agios Pharmaceuticals AGIO:US $ 5.15M 4.65M
Amarin AMRN:US $ 58.63M 13.76M
Amgen AMGN:US $ 5084M 407M
Biogen BIIB:US $ 2105.1M 327.2M
Bluebird Bio BLUE:US $ -226000 6.14M
Daiichi Sankyo 4568:JP Y 205519M 60424M
Eisai 4523:JP Y 136858M 3305M
Epizyme EPZM:US $ 22.36M 16.3M
Exelixis EXEL:US $ 405.95M 63.17M
Gilead Sciences GILD:US $ 4818M 348M
GlaxoSmithKline GSK:LN 4.79B 1.34B
Glaxosmithkline GSK:US $ 4793M 1342M
IONIS PHARMACEUT IONS:US $ 129.05M 8.7M
Karyopharm Therapeutics KPTI:US $ 38.74M 7.5M
MacroGenics MGNX:US 23.6M 12.55M
Merk MRK:US $ 10895M 328M
Novartis NOVN:VX 9.34B 277M
Novartis NVS:US $ 9336M 277M
Pfizer PFE:US $ 19071M 3420M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Seattle Genetics SGEN:US $ 391.4M 52.57M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M